Meta2DB: Curated Shotgun Metagenomic Feature Sets and Metadata for Health State Prediction

Car Reen Kok[1], Nisha J. Mulakken[1], James B. Thissen[1], Jose Manuel Martí[1], Ryan Lee[1,2], Jacob B. Trainer[1], Andre R. Goncalves[1], Hiranmayi Ranganathan[1], Aram Avila-Herrera[1], Crystal J. Jaing[1], Nicholas A. Be[1]

[1]Lawrence Livermore National Laboratory, Livermore, CA
[2]University of California, Merced, Merced, CA

Corresponding author: Nicholas A. Be, Ph.D.
Biosciences and Biotechnology Division
Lawrence Livermore National Laboratory
Livermore, CA 94550
Tel: 925-423-1612
Email: be1@llnl.gov

ABSTRACT

Meta2DB is a curated metagenomic and metadata database that provides

structurally consistent microbiome taxonomy feature count tables for 13,897 samples

across 84 studies, 23 disease states, and 34 geographical locations. All samples were

uniformly processed using a streamlined metagenomic classification pipeline that

employs a reference database indexed to contain all sequences across all kingdoms of

life that were present in the NCBI Nucleotide (nt) database retrieved on Jan 04, 2023.

This pipeline leverages high-performance computing (HPC) resources at Lawrence

Livermore National Laboratory and was used to process 50TB of publicly available raw

metagenomic sequence data. Extensive metadata curation was carried out through a

combination of manual curation and automated parsing, producing a consistent inter-

study metadata table specifically structured to facilitate training of ML models for

prediction of human health.

INTRODUCTION

The human microbiome represents a target with tremendous potential for diagnosing and predicting human health. Microbiome features have been indicated as prognostic factors for a range of disease states, including cancer, gut health disruption, neurodegenerative disease, environmental exposure, and mental health. Development of models that leverage microbiome features for prediction of human health states could facilitate tools with clinically actionable utility and identify microbiome-centric variables for therapeutic intervention.

Machine learning (ML), and specifically deep learning (DL), approaches have demonstrated potential in exploring and classifying microbiomes in the context of human health [1, 2]. Convolutional neural networks (CNNs) have demonstrated the capacity to predict various modes of disease outcomes such as disease severity in ulcerative colitis, cirrhosis and inflammatory bowel disease using microbiome-derived data [3-5].

Microbiome data employed for predictive modeling are often derived from metagenomic sequence data generated from the specimens of interest. Such profiling can involve amplicon sequencing, where a specific gene or region is amplified and assigned to microbial taxonomy, most often the bacterial 16S rRNA sequence. Alternatively, shotgun metagenomic sequencing can be performed, whereby all gDNA within an extracted specimen are sequenced and the resultant sequence reads are aligned to references via a metagenomic classification software platform. The output from such analyses is a feature table, where a taxonomic identifier for a given taxonomic rank (e.g., genus, species) is assigned a numeric value (number of classified

sequences), which can then be transformed as desired and used as input for the ML

platform of choice.

The high-dimensional nature of microbiome data derived from many features (p)

alongside small sample sizes (n) often result in large p and small n datasets. This

presents a critical challenge in ML modeling, resulting in overfitting and limiting

generalizability to new or unseen data. One strategy for sample size expansion is to

integrate publicly available datasets across different studies. While health-relevant

microbiome datasets are becoming increasingly available, dataset integration for use in

a cohesive model training approach is difficult as 1) microbiome feature tables are

generated by distinct metagenomic classification platforms that impart systematic

biases, 2) independent studies implement distinct quality and sequence filtering steps,

and 3) metadata are inconsistently and sparsely represented.

One avenue for addressing this need is to perform a meta-acquisition of the raw

sequencing data corresponding to many parallel studies, and to process all such

datasets via one consistent metagenomic classification pipeline. The Human

Microbiome Compendium [6] and the curatedMetagenomicData data package [7]

implements such an approach providing an excellent resource for consistently

structured microbiome profiles across multiple studies using 16S rRNA amplicon

sequencing and shotgun metagenomic sequencing respectively. The Human

Microbiome Compendium pipeline incorporates the DADA2 algorithm [8] to produce

Amplicon Sequence Variants for taxonomic identification. The profiles contained in the

curatedMetagenomicData data package are produced via MetaPhlAn3 [9], which

employs a marker library reference for assigning shotgun metagenomic data, leveraging

the benefits of increased taxonomic resolution of shotgun sequence. The marker library

facilitates a computationally efficient workflow, though it is limited to the taxonomic

entities for which markers are identified and indexed.

Our approach (**Figure 1**) employs a reference database indexed to contain all

sequences present in NCBI Nucleotide (nt) from all kingdoms of life [10] (Database

available here: https://benlangmead.github.io/aws-indexes/centrifuge). This approach is

inherently more comprehensive and high resolution, but computationally intensive. To

provide a complementary resource for microbiome-centric model training, we leveraged

high-performance computing (HPC) resources at Lawrence Livermore National

Laboratory to perform metagenomic classification on 50TB of publicly available raw

metagenomic sequence data. We generated structurally consistent microbiome

taxonomy feature count tables for 13,897 samples, spanning across 84 studies [11-94].

We further performed extensive metadata curation of all assessed studies through a

combination of manual curation and automated parsing, producing a consistent inter-

study metadata table specifically structured to facilitate training of ML models for

prediction of human health. These curated datasets are available here as supplemental

material and will soon be hosted on a website (Meta2DB) whereby a user interface

supported by relational databases is available for data exploration.

Figure 1. Meta2DB pipeline for the curation of shotgun metagenomic data. A) Data

intake, processing and integration of publicly available shotgun metagenomic

sequences and associated metadata. B) UMAP plot of 13,897 samples based on

computed Euclidean distances. Samples are colored according to different health and

disease states. C) Meta2DB web interface for data download and exploration.

METHODS

Selection of studies for meta-analysis

Literature studies were selected for data intake and curation if they met each of the following requirements: 1) biospecimens were processed via whole metagenome short-read sequencing using an Illumina platform, 2) raw sequence data and study metadata were publicly accessible, 3) the study was performed in the context of one or more defined human disease states, and 4) each assessed biospecimen could be assigned one of two binary labels corresponding to "control" or "diseased."

The data collection process includes leveraging an existing resource of curated microbiome data and conducting a strategic search in PubMed. The curatedMetagenomicData package is a pre-existing, well-curated collection of studies, many of which met the characteristics described above [95]. A subset of studies from this curated package was selected for inclusion. To supplement this list of studies, a literature search was carried out in PubMed to retrieve relevant articles. The following search terms were used in combination; "shotgun", "metagenomics", "disease", and studies were manually curated to ensure that they met the requirements listed above.

These parameters were selected for consistency with the aim of facilitating downstream analyses; it is however acknowledged that future analyses could benefit from incorporation of additional data modalities such as amplicon sequences and long-read sequencing, which will be the subject of future iterations.

Metadata curation

Metadata was extracted from multiple potential sources depending on the individual study of interest, including from the publication and supplementary data or

sequence repository. Data sources also included large databases, like the Inflammatory

Bowel Disease database of the iHMP, which contains thousands of metagenomics

samples from patients with either Crohn's Disease (CD) or ulcerative colitis (UC), as

well as control samples. The Genomic Standards Consortium's Minimum Information

about any Sequence (MIxS) metadata standards were used to group and standardize

patient health, treatment, and demographic metadata across all studies. Controlled

vocabulary for defined disorders and health states were used to create consistent

formatting and naming. In addition to metadata common to all studies, metadata specific

to each disorder was also preserved. Metadata around sample collection and type of

assay performed were tracked to account for possible effects on outcomes. To

distinguish different types of missing data, "not applicable" was used for fields not

relevant to a sample, "not available" was used when the data is relevant and missing,

and "none" was used when was used when a field that is a treatment is not applied to

the patient or when a health status is not observed for the patient.

Raw sequence acquisition

Raw sequence data (fastq files) were downloaded from public repositories

including the NCBI Sequence Read Archive (SRA) [96] and the European Nucleotide

Archive (ENA) [97]. The Integrative Human Microbiome Project (iHMP) sequences were

obtained from the HMP Data Coordination Center [62].

Sequence pre-processing

Raw sequence data were pre-processed via fastp [98]. These parameters

include using a qualified quality phred value of Q15, an unqualified base percentage of

40%, and a minimum read length of 15. Individual post-filtering of samples was

performed with the following read count thresholds: 5M paired-end reads for fecal

samples and 1M paired-end reads for skin, oral, and nasal samples. Samples not

meeting these thresholds were removed from downstream analysis. Reads were

subsequently aligned to the GRCh38 human reference genome using minimap2 [99] for

the removal of human reads.

Metagenomic classification

Resultant reads were processed for metagenomic classification via Centrifuge

[100], applying taxonomic labels via Lowest Common Ancestor (LCA) classification

strategy. A Minimum Hit Length (MHL) of 15 or 25 was employed for initial Centrifuge

processing. Post-processing was performed via Recentrifuge [101] to propagate and

normalize Centrifuge assignment scores and perform additional filtering. For purposes

of downstream analysis, taxonomic assignments were filtered at a MHL threshold of 40

and feature count tables were produced.

UMAP visualization

UMAP dimensionality reduction was applied to all 13,897 samples using the

umap (version 0.2.10) package in R (version 4.2.2) with default parameters

(n_neighbors=15, n_components=2, n_epochs=200). The local neighborhood structure

was constructed using the UMAP algorithm on pairwise Euclidean distances.

DATA AVAILABILITY

The processed feature tables and metadata are available here as supplemental

material. The Meta2DB website will be available soon and will host all processed

feature tables, metadata tables along with example notebooks and scripts for data

intake and analyses. The indexed version of the centrifuge database based on the

entirety of NCBI nt is available at https://benlangmead.github.io/aws-indexes/centrifuge

for processing of datasets not included in Meta2DB.

COMPETING INTERESTS

Not applicable

FUNDING

This study received internal financial support from an award at Lawrence Livermore

National Laboratory.

ACKNOWLEDGEMENTS

This work was performed under the auspices of the U.S. Department of Energy by

Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344. LLNL

Disclaimer: This document was prepared as an account of work sponsored by an

agency of the United States government. Neither the United States government nor

Lawrence Livermore National Security, LLC, nor any of their employees makes any

warranty, expressed or implied, or assumes any legal liability or responsibility for the

accuracy, completeness, or usefulness of any information, apparatus, product, or

process disclosed, or represents that its use would not infringe privately owned rights.

Reference herein to any specific commercial product, process, or service by trade

name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its

endorsement, recommendation, or favoring by the United States government or

Lawrence Livermore National Security, LLC. The views and opinions of authors

expressed herein do not necessarily state or reflect those of the United States

government or Lawrence Livermore National Security, LLC, and shall not be used for

advertising or product endorsement purposes.

208
209 **REFERENCES**
210

1. Namkung J. Machine learning methods for microbiome studies. Journal of
Microbiology. 2020;58(3):206-16; doi: 10.1007/s12275-020-0066-8.
2. Wang Y, Bhattacharya T, Jiang Y, Qin X, Wang Y, Liu Y, et al. A novel deep
learning method for predictive modeling of microbiome data. Briefings in
Bioinformatics. 2020;22(3); doi: 10.1093/bib/bbaa073.
3. Fung DLX, Li X, Leung CK, Hu P. A self-knowledge distillation-driven CNN-LSTM
model for predicting disease outcomes using longitudinal microbiome data.
Bioinformatics Advances. 2023;3(1); doi: 10.1093/bioadv/vbad059.
4. Lo C, Marculescu R. MetaNN: accurate classification of host phenotypes from
metagenomic data using neural networks. BMC Bioinformatics. 2019;20(12):314;
doi: 10.1186/s12859-019-2833-2.
5. Sharma D, Paterson AD, Xu W. TaxoNN: ensemble of neural networks on
stratified microbiome data for disease prediction. Bioinformatics.
2020;36(17):4544-50; doi: 10.1093/bioinformatics/btaa542.
6. Abdill RJ, Graham SP, Rubinetti V, Albert FW, Greene CS, Davis S, et al.
Integration of 168,000 samples reveals global patterns of the human gut
microbiome. bioRxiv. 2023:2023.10.11.560955; doi: 10.1101/2023.10.11.560955.
7. Pasolli E, Schiffer L, Manghi P, Renson A, Obenchain V, Truong DT, et al.
Accessible, curated metagenomic data through ExperimentHub. Nature Methods.
2017;14(11):1023-4; doi: 10.1038/nmeth.4468.
8. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP.
DADA2: High-resolution sample inference from Illumina amplicon data. Nature
Methods. 2016;13(7):581-3; doi: 10.1038/nmeth.3869.
9. Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, et al.
Integrating taxonomic, functional, and strain-level profiling of diverse microbial
communities with bioBakery 3. eLife. 2021;10:e65088; doi: 10.7554/eLife.65088.
10. Martí JM, Kok CR, Thissen JB, Mulakken NJ, Avila-Herrera A, Jaing CJ, et al.
Addressing the dynamic nature of reference data: a new nt database for robust
metagenomic classification. bioRxiv. 2024:2024.06.12.598617; doi:
10.1101/2024.06.12.598617.
11. Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, et al.
Microbiome connections with host metabolism and habitual diet from 1,098
deeply phenotyped individuals. Nat Med. 2021;27(2):321-32; doi:
10.1038/s41591-020-01183-8.

12. Asnicar F, Manara S, Zolfo M, Truong DT, Scholz M, Armanini F, et al. Studying
Vertical Microbiome Transmission from Mothers to Infants by Strain-Level
Metagenomic Profiling. mSystems. 2017;2(1); doi: 10.1128/mSystems.00164-16.
13. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al.
Dynamics and Stabilization of the Human Gut Microbiome during the First Year
of Life. Cell Host Microbe. 2015;17(5):690-703; doi: 10.1016/j.chom.2015.04.004.
14. Bai X, Narayanan A, Skagerberg M, Ceña-Diez R, Giske CG, Strålin K, et al.
Characterization of the Upper Respiratory Bacterial Microbiome in Critically Ill
COVID-19 Patients. Biomedicines. 2022;10(5):982.
15. Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, et al.
Functional implications of microbial and viral gut metagenome changes in early
stage L-DOPA-naïve Parkinson's disease patients. Genome Med. 2017;9(1):39;
doi: 10.1186/s13073-017-0428-y.
16. Bengtsson-Palme J, Angelin M, Huss M, Kjellqvist S, Kristiansson E, Palmgren
H, et al. The Human Gut Microbiome as a Transporter of Antibiotic Resistance
Genes between Continents. Antimicrob Agents Chemother. 2015;59(10):6551-
60; doi: 10.1128/aac.00933-15.
17. Boktor JC, Sharon G, Verhagen Metman LA, Hall DA, Engen PA, Zreloff Z, et al.
Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome.
Mov Disord. 2023;38(3):399-409; doi: 10.1002/mds.29300.
18. Bommana S, Richards G, Kama M, Kodimerla R, Jijakli K, Read TD, et al.
Metagenomic Shotgun Sequencing of Endocervical, Vaginal, and Rectal
Samples among Fijian Women with and without Chlamydia trachomatis Reveals
Disparate Microbial Populations and Function across Anatomic Sites: a Pilot
Study. Microbiol Spectr. 2022;10(3):e0010522; doi: 10.1128/spectrum.00105-22.
19. Boolchandani M, Blake KS, Tilley DH, Cabada MM, Schwartz DJ, Patel S, et al.
Impact of international travel and diarrhea on gut microbiome and resistome
dynamics. Nature Communications. 2022;13(1):7485; doi: 10.1038/s41467-022-
34862-w.
20. Brooks B, Olm MR, Firek BA, Baker R, Thomas BC, Morowitz MJ, et al. Strain-
resolved analysis of hospital rooms and infants reveals overlap between the
human and room microbiome. Nat Commun. 2017;8(1):1814; doi:
10.1038/s41467-017-02018-w.
21. Byrd AL, Deming C, Cassidy SKB, Harrison OJ, Ng WI, Conlan S, et al.
Staphylococcus aureus and Staphylococcus epidermidis strain diversity
underlying pediatric atopic dermatitis. Sci Transl Med. 2017;9(397); doi:
10.1126/scitranslmed.aal4651.
22. Castro-Nallar E, Bendall ML, Pérez-Losada M, Sabuncyan S, Severance EG,
Dickerson FB, et al. Composition, taxonomy and functional diversity of the
oropharynx microbiome in individuals with schizophrenia and controls. PeerJ.
2015;3:e1140; doi: 10.7717/peerj.1140.
23. Chang H-W, Yan D, Singh R, Bui A, Lee K, Truong A, et al. Multiomic Analysis of
the Gut Microbiome in Psoriasis Reveals Distinct Host–Microbe Associations. JID
Innovations. 2022;2(3):100115; doi: 10.1016/j.xjidi.2022.100115.

24. Chng KR, Tay AS, Li C, Ng AH, Wang J, Suri BK, et al. Whole metagenome
profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis
flare. Nat Microbiol. 2016;1(9):16106; doi: 10.1038/nmicrobiol.2016.106.
25. David LA, Weil A, Ryan ET, Calderwood SB, Harris JB, Chowdhury F, et al. Gut
microbial succession follows acute secretory diarrhea in humans. mBio.
2015;6(3):e00381-15; doi: 10.1128/mBio.00381-15.
26. Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR, Kaakoush NO.
Signatures within the esophageal microbiome are associated with host genetics,
age, and disease. Microbiome. 2018;6(1):227; doi: 10.1186/s40168-018-0611-4.
27. Espinoza JL, Harkins DM, Torralba M, Gomez A, Highlander SK, Jones MB, et
al. Supragingival Plaque Microbiome Ecology and Functional Potential in the
Context of Health and Disease. mBio. 2018;9(6); doi: 10.1128/mBio.01631-18.
28. Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome
development along the colorectal adenoma-carcinoma sequence. Nat Commun.
2015;6:6528; doi: 10.1038/ncomms7528.
29. Ferreiro AL, Choi J, Ryou J, Newcomer EP, Thompson R, Bollinger RM, et al.
Gut microbiome composition may be an indicator of preclinical Alzheimer's
disease. Science Translational Medicine. 2023;15(700):eabo2984; doi:
doi:10.1126/scitranslmed.abo2984.
30. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S,
et al. Gut microbiome structure and metabolic activity in inflammatory bowel
disease. Nat Microbiol. 2019;4(2):293-305; doi: 10.1038/s41564-018-0306-4.
31. Ghensi P, Manghi P, Zolfo M, Armanini F, Pasolli E, Bolzan M, et al. Strong oral
plaque microbiome signatures for dental implant diseases identified by strain-
resolution metagenomics. NPJ Biofilms Microbiomes. 2020;6(1):47; doi:
10.1038/s41522-020-00155-7.
32. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV,
et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in
melanoma patients. Science. 2018;359(6371):97-103; doi:
10.1126/science.aan4236.
33. Guillén Y, Noguera-Julian M, Rivera J, Casadellà M, Zevin AS, Rocafort M, et al.
Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. Mucosal
Immunol. 2019;12(1):232-46; doi: 10.1038/s41385-018-0083-7.
34. Guo C, Che X, Briese T, Ranjan A, Allicock O, Yates RA, et al. Deficient
butyrate-producing capacity in the gut microbiome is associated with bacterial
network disturbances and fatigue symptoms in ME/CFS. Cell Host Microbe.
2023;31(2):288-304.e8; doi: 10.1016/j.chom.2023.01.004.
35. Gupta A, Dhakan DB, Maji A, Saxena R, P KV, Mahajan S, et al. Association of
Flavonifractor plautii, a Flavonoid-Degrading Bacterium, with the Gut Microbiome
of Colorectal Cancer Patients in India. mSystems. 2019;4(6); doi:
10.1128/mSystems.00438-19.
36. Hall AB, Yassour M, Sauk J, Garner A, Jiang X, Arthur T, et al. A novel
Ruminococcus gnavus clade enriched in inflammatory bowel disease patients.
Genome Med. 2017;9(1):103; doi: 10.1186/s13073-017-0490-5.

37. Hannigan GD, Duhaime MB, Ruffin MTt, Koumpouras CC, Schloss PD. Diagnostic Potential and Interactive Dynamics of the Colorectal Cancer Virome. mBio. 2018;9(6); doi: 10.1128/mBio.02248-18.

38. Heintz-Buschart A, May P, Laczny CC, Lebrun LA, Bellora C, Krishna A, et al. Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes. Nat Microbiol. 2016;2:16180; doi: 10.1038/nmicrobiol.2016.180.

39. Hu Y, Feng Y, Wu J, Liu F, Zhang Z, Hao Y, et al. The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients. Front Cell Infect Microbiol. 2019;9:90; doi: 10.3389/fcimb.2019.00090.

40. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8(1):845; doi: 10.1038/s41467-017-00900-1.

41. Jo S, Kang W, Hwang YS, Lee SH, Park KW, Kim MS, et al. Oral and gut dysbiosis leads to functional alterations in Parkinson's disease. NPJ Parkinsons Dis. 2022;8(1):87; doi: 10.1038/s41531-022-00351-6.

42. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103; doi: 10.1038/nature12198.

43. Khachatryan L, Xiang Y, Ivanov A, Glaab E, Graham G, Granata I, et al. Results and lessons learned from the sbv IMPROVER metagenomics diagnostics for inflammatory bowel disease challenge. Sci Rep. 2023;13(1):6303; doi: 10.1038/s41598-023-33050-0.

44. Kieser S, Sarker SA, Sakwinska O, Foata F, Sultana S, Khan Z, et al. Bangladeshi children with acute diarrhoea show faecal microbiomes with increased Streptococcus abundance, irrespective of diarrhoea aetiology. Environ Microbiol. 2018;20(6):2256-69; doi: 10.1111/1462-2920.14274.

45. Laske C, Müller S, Preische O, Ruschil V, Munk MHJ, Honold I, et al. Signature of Alzheimer's Disease in Intestinal Microbiome: Results From the AlzBiom Study. Front Neurosci. 2022;16:792996; doi: 10.3389/fnins.2022.792996.

46. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14; doi: 10.1186/s40168-016-0222-x.

47. Lin B, Wang M, Gao R, Ye Z, Yu Y, He W, et al. Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma. Microbiol Spectr. 2022;10(1):e0042521; doi: 10.1128/spectrum.00425-21.

48. Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544-52; doi: 10.1136/gutjnl-2021-325989.

49. Loman NJ, Constantinidou C, Christner M, Rohde H, Chan JZ, Quick J, et al. A culture-independent sequence-based metagenomics approach to the investigation of an outbreak of Shiga-toxigenic Escherichia coli O104:H4. Jama. 2013;309(14):1502-10; doi: 10.1001/jama.2013.3231.

50. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25(5):1054-62.e5; doi: 10.1016/j.cmet.2017.04.001.

379   51.   Mancabelli L, Milani C, Lugli GA, Turroni F, Mangifesta M, Viappiani A, et al.
380   Unveiling the gut microbiota composition and functionality associated with
381   constipation through metagenomic analyses. Sci Rep. 2017;7(1):9879; doi:
382   10.1038/s41598-017-10663-w.
383   52.   Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The
384   commensal microbiome is associated with anti-PD-1 efficacy in metastatic
385   melanoma patients. Science. 2018;359(6371):104-8; doi:
386   10.1126/science.aao3290.
387   53.   Maya-Lucas O, Murugesan S, Nirmalkar K, Alcaraz LD, Hoyo-Vadillo C, Pizano-
388   Zárate ML, et al. The gut microbiome of Mexican children affected by obesity.
389   Anaerobe. 2019;55:11-23; doi: 10.1016/j.anaerobe.2018.10.009.
390   54.   McDonald D, Hyde E, Debelius JW, Morton JT, Gonzalez A, Ackermann G, et al.
391   American Gut: an Open Platform for Citizen Science Microbiome Research.
392   mSystems. 2018;3(3):10.1128/msystems.00031-18; doi:
393   doi:10.1128/msystems.00031-18.
394   55.   Nagata N, Nishijima S, Kojima Y, Hisada Y, Imbe K, Miyoshi-Akiyama T, et al.
395   Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer
396   From a Multinational Study. Gastroenterology. 2022;163(1):222-38; doi:
397   10.1053/j.gastro.2022.03.054.
398   56.   Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, et al. Fecal
399   metagenomic profiles in subgroups of patients with myalgic
400   encephalomyelitis/chronic fatigue syndrome. Microbiome. 2017;5(1):44; doi:
401   10.1186/s40168-017-0261-y.
402   57.   Oh S, Yap GC, Hong PY, Huang CH, Aw MM, Shek LP, et al. Immune-
403   modulatory genomic properties differentiate gut microbiota of infants with and
404   without eczema. PLoS One. 2017;12(10):e0184955; doi:
405   10.1371/journal.pone.0184955.
406   58.   Olm MR, Brown CT, Brooks B, Firek B, Baker R, Burstein D, et al. Identical
407   bacterial populations colonize premature infant gut, skin, and oral microbiomes
408   and exhibit different in situ growth rates. Genome Res. 2017;27(4):601-12; doi:
409   10.1101/gr.213256.116.
410   59.   Pienkowska K, Pust MM, Gessner M, Gaedcke S, Thavarasa A, Rosenboom I, et
411   al. The Cystic Fibrosis Upper and Lower Airway Metagenome. Microbiol Spectr.
412   2023;11(2):e0363322; doi: 10.1128/spectrum.03633-22.
413   60.   Piper HG, Fan D, Coughlin LA, Ho EX, McDaniel MM, Channabasappa N, et al.
414   Severe Gut Microbiota Dysbiosis Is Associated With Poor Growth in Patients
415   With Short Bowel Syndrome. JPEN J Parenter Enteral Nutr. 2017;41(7):1202-12;
416   doi: 10.1177/0148607116658762.
417   61.   Polster SP, Sharma A, Tanes C, Tang AT, Mericko P, Cao Y, et al. Permissive
418   microbiome characterizes human subjects with a neurovascular disease
419   cavernous angioma. Nat Commun. 2020;11(1):2659; doi: 10.1038/s41467-020-
420   16436-w.
421   62.   Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, et al.
422   The Integrative Human Microbiome Project. Nature. 2019;569(7758):641-8; doi:
423   10.1038/s41586-019-1238-8.

63. Pust MM, Wiehlmann L, Davenport C, Rudolf I, Dittrich AM, Tümmler B. The human respiratory tract microbial community structures in healthy and cystic fibrosis infants. NPJ Biofilms Microbiomes. 2020;6(1):61; doi: 10.1038/s41522-020-00171-7.

64. Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;25(8):1225-33; doi: 10.1038/s41591-019-0509-0.

65. Qian Y, Yang X, Xu S, Huang P, Li B, Du J, et al. Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease. Brain. 2020;143(8):2474-89; doi: 10.1093/brain/awaa201.

66. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59-64; doi: 10.1038/nature13568.

67. Rosa BA, Supali T, Gankpala L, Djuardi Y, Sartono E, Zhou Y, et al. Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia. Microbiome. 2018;6(1):33; doi: 10.1186/s40168-018-0416-5.

68. Rubel MA, Abbas A, Taylor LJ, Connell A, Tanes C, Bittinger K, et al. Lifestyle and the presence of helminths is associated with gut microbiome composition in Cameroonians. Genome Biol. 2020;21(1):122; doi: 10.1186/s13059-020-02020-4.

69. Sankaranarayanan K, Ozga AT, Warinner C, Tito RY, Obregon-Tito AJ, Xu J, et al. Gut Microbiome Diversity among Cheyenne and Arapaho Individuals from Western Oklahoma. Curr Biol. 2015;25(24):3161-9; doi: 10.1016/j.cub.2015.10.060.

70. Shi B, Chang M, Martin J, Mitreva M, Lux R, Klokkevold P, et al. Dynamic changes in the subgingival microbiome and their potential for diagnosis and prognosis of periodontitis. mBio. 2015;6(1):e01926-14; doi: 10.1128/mBio.01926-14.

71. Sun H, Guo Y, Wang H, Yin A, Hu J, Yuan T, et al. Gut commensal Parabacteroides distasonis alleviates inflammatory arthritis. Gut. 2023;72(9):1664-77; doi: 10.1136/gutjnl-2022-327756.

72. Sun Z, Zhang M, Li M, Bhaskar Y, Zhao J, Ji Y, et al. Interactions between Human Gut Microbiome Dynamics and Sub-Optimal Health Symptoms during Seafaring Expeditions. Microbiol Spectr. 2022;10(1):e0092521; doi: 10.1128/spectrum.00925-21.

73. Tay ASL, Li C, Nandi T, Chng KR, Andiappan AK, Mettu VS, et al. Atopic dermatitis microbiomes stratify into ecologic dermotypes enabling microbial virulence and disease severity. J Allergy Clin Immunol. 2021;147(4):1329-40; doi: 10.1016/j.jaci.2020.09.031.

74. Ventura RE, Iizumi T, Battaglia T, Liu M, Perez-Perez GI, Herbert J, et al. Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course. Sci Rep. 2019;9(1):16396; doi: 10.1038/s41598-019-52894-z.

75. Vincent C, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and

Clostridium difficile colonization or infection. Microbiome. 2016;4:12; doi: 10.1186/s40168-016-0156-3.

76. Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, et al. Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms. Nature Communications. 2022;13(1):6958; doi: 10.1038/s41467-022-34667-x.

77. Wang Z, Liang L, Liu L, Wang Z, Wang Y, Yu Z, et al. Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome. Microbiol Spectr. 2023;11(2):e0281922; doi: 10.1128/spectrum.02819-22.

78. Wen C, Zheng Z, Shao T, Liu L, Xie Z, Le Chatelier E, et al. Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis. Genome Biol. 2017;18(1):142; doi: 10.1186/s13059-017-1271-6.

79. Weng YJ, Gan HY, Li X, Huang Y, Li ZC, Deng HM, et al. Correlation of diet, microbiota and metabolite networks in inflammatory bowel disease. J Dig Dis. 2019;20(9):447-59; doi: 10.1111/1751-2980.12795.

80. Xiong R, Gunter C, Fleming E, Vernon SD, Bateman L, Unutmaz D, et al. Multi-'omics of gut microbiome-host interactions in short- and long-term myalgic encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe. 2023;31(2):273-87.e5; doi: 10.1016/j.chom.2023.01.001.

81. Xiong Z, Peng K, Song S, Zhu Y, Gu J, Huang C, et al. Cerebral Intraparenchymal Hemorrhage Changes Patients' Gut Bacteria Composition and Function. Front Cell Infect Microbiol. 2022;12:829491; doi: 10.3389/fcimb.2022.829491.

82. Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019;25(6):968-76; doi: 10.1038/s41591-019-0458-7.

83. Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, et al. Alterations of the Gut Microbiome in Hypertension. Front Cell Infect Microbiol. 2017;7:381; doi: 10.3389/fcimb.2017.00381.

84. Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, et al. A metagenomic study of the gut microbiome in Behcet's disease. Microbiome. 2018;6(1):135; doi: 10.1186/s40168-018-0520-6.

85. Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70-8; doi: 10.1136/gutjnl-2015-309800.

86. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10(11):766; doi: 10.15252/msb.20145645.

87. Zhang F, Wan Y, Zuo T, Yeoh YK, Liu Q, Zhang L, et al. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19. Gastroenterology. 2022;162(2):548-61.e4; doi: 10.1053/j.gastro.2021.10.013.

88. Zhou T, Wu J, Zeng Y, Li J, Yan J, Meng W, et al. SARS-CoV-2 triggered oxidative stress and abnormal energy metabolism in gut microbiota. MedComm (2020). 2022;3(1):e112; doi: 10.1002/mco2.112.

89. Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, et al. Metagenome-wide association of gut microbiome features for schizophrenia. Nat Commun. 2020;11(1):1612; doi: 10.1038/s41467-020-15457-9.

90. Zhu Q, Hou Q, Huang S, Ou Q, Huo D, Vázquez-Baeza Y, et al. Compositional and genetic alterations in Graves' disease gut microbiome reveal specific diagnostic biomarkers. Isme j. 2021;15(11):3399-411; doi: 10.1038/s41396-021-01016-7.

91. Zinkernagel MS, Zysset-Burri DC, Keller I, Berger LE, Leichtle AB, Largiadèr CR, et al. Association of the Intestinal Microbiome with the Development of Neovascular Age-Related Macular Degeneration. Sci Rep. 2017;7:40826; doi: 10.1038/srep40826.

92. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159(3):944-55.e8; doi: 10.1053/j.gastro.2020.05.048.

93. Zuo W, Wang B, Bai X, Luan Y, Fan Y, Michail S, et al. 16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis. Sci Rep. 2022;12(1):6421; doi: 10.1038/s41598-022-07995-7.

94. Zysset-Burri DC, Keller I, Berger LE, Largiadèr CR, Wittwer M, Wolf S, et al. Associations of the intestinal microbiome with the complement system in neovascular age-related macular degeneration. NPJ Genom Med. 2020;5:34; doi: 10.1038/s41525-020-00141-0.

95. Pasolli E, Schiffer L, Manghi P, Renson A, Obenchain V, Truong DT, et al. Accessible, curated metagenomic data through ExperimentHub. Nat Methods. 2017;14(11):1023-4; doi: 10.1038/nmeth.4468.

96. Leinonen R, Sugawara H, Shumway M, Collaboration obotINSD. The Sequence Read Archive. Nucleic Acids Research. 2010;39(suppl_1):D19-D21; doi: 10.1093/nar/gkq1019.

97. Yuan D, Ahamed A, Burgin J, Cummins C, Devraj R, Gueye K, et al. The European Nucleotide Archive in 2023. Nucleic Acids Research. 2023;52(D1):D92-D7; doi: 10.1093/nar/gkad1067.

98. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884-i90; doi: 10.1093/bioinformatics/bty560.

99. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34(18):3094-100; doi: 10.1093/bioinformatics/bty191.

100. Kim D, Song L, Breitwieser FP, Salzberg SL. Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res. 2016;26(12):1721-9; doi: 10.1101/gr.210641.116.

101. Marti JM. Recentrifuge: Robust comparative analysis and contamination removal for metagenomics. PLoS Comput Biol. 2019;15(4):e1006967; doi: 10.1371/journal.pcbi.1006967.